2 abril 2015
With each new amyloid-targeting treatment for Alzheimer’s disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-beta peptide produce inflammation in the brain in some patients. Gamma secretase inhibitors tend to produce adverse effects by interacting with Notch, an important pathway for cellular signaling. Beta secretase 1 (BACE1) inhibitors are a new and promising target for Alzheimer’s disease. Inhibiting BACE1 will limit the production of amyloid-beta which, in turn, should reduce the production of neurotoxic fibrils and plaques, scientists say.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/Hhby9ZGJKek/150402092059.htm
